impedance cardiography

(redirected from Thoracic electrical bioimpedance)

impedance cardiography

Abbreviation: ICG
A noninvasive means of determining cardiac output in which the stroke volume of each cardiac contraction is determined by measuring beat-to-beat changes in the electrical impedance of the chest and neck.
Synonym: electrical impedance plethysmography
See also: cardiography
References in periodicals archive ?
the IQ2(TM), an impedance cardiograph, or ICG, device that uses thoracic electrical bioimpedance, or TEB, to noninvasively monitor hemodynamics (the blood flow, cardiac output, cardiac index, stroke volume, heart rate and other aspects of left ventricular performance).
Background: Little has been written about the utility of thoracic electrical bioimpedance (TEB)-derived cardiac physiologic variables in evaluating patients with low-risk chest pain syndromes.
com(TM), use Thoracic Electrical Bioimpedance (TEB) technology to obtain data which is typically available only through the time-consuming, costly and potentially dangerous invasive Pulmonary Artery Catheterization (PAC) procedure.
com, the world's smallest, most cost-effective, full-featured Thoracic Electrical Bioimpedance product.
LIFEGARD II with ICG (Impedance CardioGraphy) uses Thoracic Electrical Bioimpedance (TEB) to measure continuous cardiac output, and is the only patient monitor that has ICG totally integrated with all other standard, non-invasive vital signs.
ICG is based on enhanced thoracic electrical bioimpedance technology, which allows a simple, quick, and easy method for clinicians to perform hemodynamic assessment or continuous monitoring of a patient's hemodynamic status.
Perry, chief executive officer of CardioDynamics, stated, "One of the major benefits of the BioZ's proprietary Thoracic Electrical Bioimpedance (TEB) technology is its usefulness in a vast range of applications.
The study demonstrates that CardioDynamics' proprietary noninvasive Thoracic Electrical Bioimpedance (TEB) technology can significantly reduce healthcare expenditures by providing an alternative to the costly, risky and invasive Pulmonary Artery Catheter (PAC).
The studies further validated that CardioDynamics' proprietary noninvasive Thoracic Electrical Bioimpedance (TEB) technology accurately measures cardiac output as compared to measurements by Intermittent Bolus Thermodilution (IBTD) from a Pulmonary Artery Catheter (PAC), as well as the long standing "gold standard," Direct Fick.
The studies demonstrated that CardioDynamics' proprietary Thoracic Electrical Bioimpedance (TEB) technology accurately and inexpensively measures cardiac performance in both hospital critical care units and outpatient physician office settings.
The company credited the strong second quarter sales growth to the focused sales efforts of its domestic sales force and international distributor network, the positive effects of Health Care Financing Administration's (HCFA) decision mandating full nationwide Medicare reimbursement coverage, and the growing healthcare community's recognition of the validity and clinical usefulness of the BioZ's Thoracic Electrical Bioimpedance (TEB) technology.
com(TM) utilize its proprietary Thoracic Electrical Bioimpedance (TEB) technology to noninvasively obtain data on a wide range of hemodynamic parameters.